Martine J. Piccart

Brussels, BRU, Belgium

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 134 publications

Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2- -associated high-risk HER2-negative early breast cancer: Updated results from the OlympiA phase III trial.

Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2- -associated high-risk HER2-negative early breast cancer: Updated results from the OlympiA phase III trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: February 25, 2026

Long-term immune response to mRNA anti-SARS-CoV-2 vaccination in patients with cancer.

Long-term immune response to mRNA anti-SARS-CoV-2 vaccination in patients with cancer.

Journal: Frontiers in immunology

Published: February 23, 2026

Decluttering chemotherapy agents for HER2+early breast cancer: Do we still need carboplatin?

Decluttering chemotherapy agents for HER2+early breast cancer: Do we still need carboplatin?

Journal: European journal of cancer (Oxford, England : 1990)

Published: February 20, 2026

Postmastectomy radiation therapy in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer: a retrospective exploratory cohort analysis of the adjuvant lapatinib and/or trastuzumab treatment optimization (ALTTO) trial [BIG 2-06/NCCTG N063D (Alliance)].

Postmastectomy radiation therapy in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer: a retrospective exploratory cohort analysis of the adjuvant lapatinib and/or trastuzumab treatment optimization (ALTTO) trial [BIG 2-06/NCCTG N063D (Alliance)].

Journal: EClinicalMedicine

Published: February 09, 2026

Updated results of the POSITIVE (Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine Responsive Breast Cancer) trial.

Updated results of the POSITIVE (Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine Responsive Breast Cancer) trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: January 22, 2026

Updated Results of the POSITIVE (Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine Responsive Breast Cancer) Trial.

Updated Results of the POSITIVE (Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine Responsive Breast Cancer) Trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: January 22, 2026

Manual, digital, and AI tumour-infiltrating lymphocyte scoring: a secondary analysis of the APHINITY randomised trial.

Manual, digital, and AI tumour-infiltrating lymphocyte scoring: a secondary analysis of the APHINITY randomised trial.

Journal: The Lancet. Oncology

Published: January 19, 2026

Enhancing Clinical Cancer Research Through Sharing of Data and Biospecimens.

Enhancing Clinical Cancer Research Through Sharing of Data and Biospecimens.

Journal: JAMA oncology

Published: December 18, 2025

The benefit of adjuvant pertuzumab and trastuzumab according to estrogen receptor and HER2 expression: a Sub-analysis of the APHINITY trial.

The benefit of adjuvant pertuzumab and trastuzumab according to estrogen receptor and HER2 expression: a Sub-analysis of the APHINITY trial.

Journal: Journal of the National Cancer Institute

Published: December 04, 2025

Invest where impact begins: recommendations from Breast Cancer Research Foundation Early Career Investigator Working Group (Part 1 of 2).

Invest where impact begins: recommendations from Breast Cancer Research Foundation Early Career Investigator Working Group (Part 1 of 2).

Journal: NPJ breast cancer

Published: November 28, 2025

Artificial intelligence-based tumour infiltrating lymphocyte quantification in patients with triple-negative breast cancer: an independent validation study.

Artificial intelligence-based tumour infiltrating lymphocyte quantification in patients with triple-negative breast cancer: an independent validation study.

Journal: The Lancet. Oncology

Published: November 17, 2025

The Breast International Group (BIG) Patient Partnership: Embedding meaningful patient involvement in the design and conduct of breast cancer clinical research.

The Breast International Group (BIG) Patient Partnership: Embedding meaningful patient involvement in the design and conduct of breast cancer clinical research.

Journal: Breast (Edinburgh, Scotland)

Published: November 06, 2025

Showing 1-12 of 134

Last Updated: 09/26/2026